What does PBM stand for?

Pharmacy benefit management. In the United States it usually refers to a third-party organisation administering the benefit; elsewhere, and generally in the Gulf, it more often describes the function itself, wherever it sits.

The list of medicines a plan covers, usually organised into tiers that determine how much the plan pays and how much the member pays. It is the central control in any pharmacy benefit: it decides what is available by default, what needs extra approval, and where a cheaper clinically equivalent option is offered first.

What is prior authorization, and why does it take so long?

A check before a medicine is dispensed, for drugs that are expensive, clinically risky, or appropriate only for a narrow group. It takes long when the path is manual: the prescriber assembles justification, someone reviews it, and the pharmacy waits. Automating the routine decisions is what shortens it.

A manufacturer returns an amount to the payer or plan after dispensing, usually tied to volume or to formulary placement. Because it arrives after the fact, the apparent price and the realised price differ — which is why cost analysis has to run over the whole benefit rather than claim by claim.

Is a PBM the same as an insurer?

No. An insurer carries the risk; a PBM administers the drug benefit on behalf of whoever carries it. In practice the two functions are often in the same organisation, particularly in this region, but they are distinct roles with different obligations.

How does PBM relate to DRG?

They are the two halves of what a payer pays for. DRG covers the episode of care; the pharmacy benefit covers the medicines, which for many chronic conditions is the larger and more continuous cost. Both are decisions about what is covered and at what price, made on different data.

Where does fraud, waste and abuse detection fit?

Pharmacy is one of the places it concentrates, because volumes are high and individual amounts are low enough to pass unexamined. Claim process management covers the journey from first notification through fraud detection and adjudication to settlement.

What should the analytics actually tell us?

Which drugs and categories drive cost, where utilisation is out of line with the clinical picture, how approval and rejection rates vary across prescribers and pharmacies, and where a formulary change would have the largest effect. The goal is lower prescription drug costs without cutting access to medicines patients need.

What is pharmacy benefit management?

Pharmacy benefit management (PBM) is the administration of a prescription drug benefit on behalf of a payer, health plan, employer or government: deciding which medicines are covered and on what terms, authorising them where authorisation is required, adjudicating the pharmacy claims, managing the pharmacy network, and controlling what the benefit costs without cutting access to the medicines patients need.

By NANO Health Suite Clinical & Coding Team · Last updated 2026-09-20

The five things a PBM actually administers

The formulary — which medicines are covered, in which tier, and on what conditions.
Authorisation — the rules deciding what can be dispensed immediately and what needs clinical review first.
Claims adjudication — processing each pharmacy claim against eligibility, coverage and pricing, and settling it.
The pharmacy network — which pharmacies are in scope and on what commercial terms.
Cost management — utilisation review, generic and therapeutic substitution, and the analytics that show where spend is actually going.

Why prior authorization is where the friction lives

Prior authorization exists for good reasons: some drugs are expensive enough, or risky enough, that dispensing without a check is irresponsible. But it is also the single largest source of friction in a pharmacy benefit — for the prescriber assembling justification, for the pharmacist waiting on a decision, and for the patient standing at the counter.

Which is why automation pays off here more than anywhere else in the benefit. If routine decisions resolve against the rules without a human touching them, clinical review time goes to the cases that genuinely need judgement, and the waiting disappears for everyone else. NANO PBM targets full automation of pharmacy approvals and claims processing for exactly that reason.

NANO PBM

Why rebates make the real cost hard to see

A rebate arrives after the medicine has been dispensed and is usually tied to volume or to where a drug sits on the formulary. The consequence is that the price a plan appears to pay and the price it ends up paying are different numbers, sometimes very different.

That is not a scandal by itself, but it does mean per-claim reporting cannot tell you what a drug costs you. Only analytics across the whole benefit, over a period long enough for the rebates to land, can — which is why the analytics layer is not an optional extra in a pharmacy benefit, it is how you know what is happening.

Three audiences, three channels

A pharmacy benefit has three distinct users and they want entirely different things. Payers need to administer the benefit and its rules. Providers and pharmacies need to submit and check authorisations and claims, and to know quickly where they stand. Members need to see their own coverage and prescriptions without phoning anybody.

NANO PBM puts all three on one platform — a payer portal, a provider portal and a member mobile app — which is what removes the phone calls between them rather than merely moving them.

NANO PBM

The drug data underneath

Coverage rules, interaction checking and therapeutic equivalence decisions all rest on a maintained drug knowledge base. It is the part most easily underestimated: a benefit platform is only as current as the drug data it reasons over, and a list maintained per deployment goes stale in a way nobody notices until a decision is wrong.

NANO PBM draws on NANO IDDK, the international drug data knowledge base, and NANO BRAIN reaches PBM through APIs with the approval, denial and deduction patterns it has learned across processed claims.

PBM in the Gulf

The PBM function is less separately branded here than in the United States, where three organisations administer most of the market. In the Gulf it is more often a capability inside a payer, an insurer or a health authority than a standalone intermediary — but the work is the same work, and the regulatory surface is harder, because a platform operating across several markets has to satisfy each regulator separately.

NANO PBM uses international medical classification aligned to WHO codes and is built to meet regulator requirements across more than 36 countries.

Frequently asked questions

What does PBM stand for?: Pharmacy benefit management. In the United States it usually refers to a third-party organisation administering the benefit; elsewhere, and generally in the Gulf, it more often describes the function itself, wherever it sits.
What is a formulary?: The list of medicines a plan covers, usually organised into tiers that determine how much the plan pays and how much the member pays. It is the central control in any pharmacy benefit: it decides what is available by default, what needs extra approval, and where a cheaper clinically equivalent option is offered first.
What is prior authorization, and why does it take so long?: A check before a medicine is dispensed, for drugs that are expensive, clinically risky, or appropriate only for a narrow group. It takes long when the path is manual: the prescriber assembles justification, someone reviews it, and the pharmacy waits. Automating the routine decisions is what shortens it.
How do rebates work?: A manufacturer returns an amount to the payer or plan after dispensing, usually tied to volume or to formulary placement. Because it arrives after the fact, the apparent price and the realised price differ — which is why cost analysis has to run over the whole benefit rather than claim by claim.
Is a PBM the same as an insurer?: No. An insurer carries the risk; a PBM administers the drug benefit on behalf of whoever carries it. In practice the two functions are often in the same organisation, particularly in this region, but they are distinct roles with different obligations.
How does PBM relate to DRG?: They are the two halves of what a payer pays for. DRG covers the episode of care; the pharmacy benefit covers the medicines, which for many chronic conditions is the larger and more continuous cost. Both are decisions about what is covered and at what price, made on different data.
Where does fraud, waste and abuse detection fit?: Pharmacy is one of the places it concentrates, because volumes are high and individual amounts are low enough to pass unexamined. Claim process management covers the journey from first notification through fraud detection and adjudication to settlement.
What should the analytics actually tell us?: Which drugs and categories drive cost, where utilisation is out of line with the clinical picture, how approval and rejection rates vary across prescribers and pharmacies, and where a formulary change would have the largest effect. The goal is lower prescription drug costs without cutting access to medicines patients need.

Talk to the NANO team

Tell us what you are trying to solve and we will show you how it works on your own episodes.